Ivermectin Patent Expiration
Ivermectin is Used for treating inflammatory lesions of rosacea. It was first introduced by Merck Sharp And Dohme Corp
Ivermectin Patents
Given below is the list of patents protecting Ivermectin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Sklice | US6103248 | Topical preparation and therapy for head lice |
May 22, 2018
(Expired) | Arbor Pharms Llc |
| Sklice | US8791153 | Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment-resistant strains of head lice | Oct 12, 2027 | Arbor Pharms Llc |
| Sklice | US8927595 | Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment resistant strains of head lice | Oct 12, 2027 | Arbor Pharms Llc |
| Soolantra | US10206939 | Treatment of papulopustular rosacea with ivermectin | Mar 13, 2034 | Galderma Labs Lp |
| Soolantra | US11033565 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr 22, 2024
(Expired) | Galderma Labs Lp |
| Soolantra | US5952372 | Method for treating rosacea using oral or topical ivermectin |
Sep 18, 2018
(Expired) | Galderma Labs Lp |
| Soolantra | US6133310 | Method of treatment of rosacea |
Apr 26, 2019
(Expired) | Galderma Labs Lp |
| Soolantra | US7550440 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr 22, 2024
(Expired) | Galderma Labs Lp |
| Soolantra | US8080530 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr 22, 2024
(Expired) | Galderma Labs Lp |
| Soolantra | US8093219 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr 22, 2024
(Expired) | Galderma Labs Lp |
| Soolantra | US8415311 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr 22, 2024
(Expired) | Galderma Labs Lp |
| Soolantra | US8470788 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr 22, 2024
(Expired) | Galderma Labs Lp |
| Soolantra | US8815816 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr 22, 2024
(Expired) | Galderma Labs Lp |
| Soolantra | US9089587 | Treatment of papulopustular rosacea with ivermectin | Mar 13, 2034 | Galderma Labs Lp |
| Soolantra | US9233117 | Treatment of inflammatory lesions of rosacea with ivermectin | Mar 13, 2034 | Galderma Labs Lp |
| Soolantra | US9233118 | Treatment of papulopustular rosacea with ivermectin | Mar 13, 2034 | Galderma Labs Lp |
| Soolantra | US9782425 | Treatment of papulopustular rosacea with ivermectin | Mar 13, 2034 | Galderma Labs Lp |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ivermectin's patents.
Latest Legal Activities on Ivermectin's Patents
Given below is the list recent legal activities going on the following patents of Ivermectin.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Jul, 2023 | US9233118 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Jul, 2023 | US9233117 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 03 Jul, 2023 | US8093219 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 13 Jun, 2023 | US8080530 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Jan, 2023 | US9089587 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Aug, 2022 | US10206939 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Feb, 2022 | US8815816 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 31 Jan, 2022 | US8791153 |
| Recordation of Patent Grant Mailed | 15 Jun, 2021 | US11033565 |
| Patent Issue Date Used in PTA Calculation | 15 Jun, 2021 | US11033565 |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Ivermectin Generics
Several generic applications have been filed for Ivermectin. The first generic version for Ivermectin was by Edenbridge Pharmaceuticals Llc and was approved on Oct 24, 2014. And the latest generic version is by Zydus Lifesciences Global Fze and was approved on Aug 2, 2022.
Given below is the list of companies who have filed for Ivermectin generic.
1. TARO
Taro Pharmaceutical Industries Ltd has filed for 1 generic for Ivermectin. Given below are the details of the strengths of this generic introduced by Taro.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5% | lotion | Over the counter | TOPICAL | N/A | May 6, 2020 |
2. TEVA PHARMS USA
Teva Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Ivermectin. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1% | cream | Prescription | TOPICAL | AB | Sep 13, 2019 |
| 0.5% | lotion | Discontinued | TOPICAL | N/A | Mar 21, 2022 |
3. EDENBRIDGE PHARMS
Edenbridge Pharmaceuticals Llc has filed for 1 generic for Ivermectin. Given below are the details of the strengths of this generic introduced by Edenbridge Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3MG | tablet | Prescription | ORAL | AB | Oct 24, 2014 |
4. ZYDUS LIFESCIENCES
Zydus Lifesciences Global Fze has filed for 1 generic for Ivermectin. Given below are the details of the strengths of this generic introduced by Zydus Lifesciences.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1% | cream | Prescription | TOPICAL | AB | Aug 2, 2022 |
5. PADAGIS ISRAEL
Padagis Israel Pharmaceuticals Ltd has filed for 1 generic for Ivermectin. Given below are the details of the strengths of this generic introduced by Padagis Israel.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1% | cream | Prescription | TOPICAL | AB | Apr 13, 2020 |